SEC 13F Intelligence

Endurant Capital Management LP / TREUR

Endurant Capital Management LP’s Trillium Therapeutics Inc Position

Does Endurant Capital Management LP own Trillium Therapeutics Inc (TREUR)? Not currently — the last reported position was 600.8K shares worth $6M in Q2 2021; the fund’s latest 13F (Q1 2024) no longer reports it.

Position Value
$6M
Q2 2021
Shares
600.8K
% of Portfolio
+1.60%
Quarters Held
6
position exited

Position History TREUR

Reported value by quarter
Q1 ’20: $2MQ1 ’20Q2 ’20: $5MQ2 ’20Q3 ’20: $5MQ3 ’20Q4 ’20: $10MQ4 ’20Q1 ’21: $5MQ1 ’21Q2 ’21: $6MQ2 ’21filingsflow.com
QuarterSharesValue% of Portfolio
Q2 2021600.8K$6M+1.60%
Q1 2021478.4K$5M+1.34%
Q4 2020655.7K$10M+3.48%
Q3 2020372.4K$5M+1.56%
Q2 2020677.8K$5M+0.30%
Q1 2020477.7K$2M+0.87%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Endurant Capital Management LP’s full portfolio or all institutional holders of TREUR.